Starton Therapeutics to Present at the LifeSci Partners Summer Symposium
28 juil. 2020 08h00 HE
|
Starton Therapeutics, Inc.
NEW YORK, July 28, 2020 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton” or the “Company”), a biotechnology company focused on transforming standard of care therapeutics, announced today...
Starton Therapeutics Files PCT and US Patent Application for Continuous Delivery of Lenalidomide and Class of Immunomodulatory Agents
30 avr. 2020 07h00 HE
|
Starton Therapeutics, Inc.
NEW YORK, April 30, 2020 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton” or the “Company”), a biotechnology company focused on transforming standard of care therapeutics, today announced...
Starton Successfully Completes Proof of Concept Study for Transdermal Lenalidomide
27 déc. 2019 09h00 HE
|
Starton Therapeutics, Inc.
NEW YORK, Dec. 27, 2019 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton” or the “Company”), a biotechnology company focused on transforming standard of care therapeutics, today announced the...
Starton Therapeutics: Announcing Name Change for ChemioCare Inc
26 déc. 2019 16h30 HE
|
Starton Therapeutics, Inc.
NEW YORK, Dec. 26, 2019 (GLOBE NEWSWIRE) -- ChemioCare USA Inc. (“ChemioCare” or the “Company”), a biotechnology company focused on transforming standard of care therapeutics, today announced it has...
ChemioCare Completes Successful Human Bioavailability Study for Novel 7-Day Olanzapine Transdermal Delivery System
18 déc. 2019 16h30 HE
|
ChemioCare
NEW YORK, Dec. 18, 2019 (GLOBE NEWSWIRE) -- ChemioCare USA Inc. (“ChemioCare” or the “Company”), a biotechnology company focused on transforming standard of care therapeutics, today announced the...
ChemioCare Strengthens its Proposed Slate of Directors with the Nomination of Multiple Myeloma Expert Dr. Mohamad Hussein
29 août 2019 07h40 HE
|
ChemioCare
NEW YORK, Aug. 29, 2019 (GLOBE NEWSWIRE) -- ChemioCare USA Inc. (“ChemioCare” or the “Company”), a platform company focused on proprietary transdermal delivery, announced today the addition of Dr....
ChemioCare Announces Appointment of Roy F. Waldron to Its Board of Directors
29 avr. 2019 07h50 HE
|
ChemioCare
NEW YORK, April 29, 2019 (GLOBE NEWSWIRE) -- ChemioCare USA Inc. (“ChemioCare” or the “Company”), a platform company focused on proprietary transdermal delivery, announced today the appointment of...
ChemioCare Announces Initiation of PETT Based (Permeation Enhanced Transdermal Technology) Lenalidomide Program
23 avr. 2019 08h00 HE
|
ChemioCare
NEW YORK, April 23, 2019 (GLOBE NEWSWIRE) -- ChemioCare USA Inc. (“ChemioCare” or the “Company”), a platform company focused on proprietary transdermal delivery, announced today the Company is...
ChemioCare Reports Positive Animal Study Results for CMIO-Ondan Patch
06 févr. 2019 08h29 HE
|
ChemioCare
NEW YORK, Feb. 06, 2019 (GLOBE NEWSWIRE) -- ChemioCare USA Inc. (“ChemioCare” or the “Company”), a platform company based on proprietary transdermal delivery, today announced the minipig safety and...
ChemioCare Strengthens Executive Management Team
07 janv. 2019 10h00 HE
|
ChemioCare
NEW YORK, Jan. 07, 2019 (GLOBE NEWSWIRE) -- ChemioCare USA Inc. (“ChemioCare” or the “Company”), a Platform Company based on proprietary transdermal delivery today announced the appointment of Jamie...